Nilai Agregat Aset: ProMIS (PMN)

ProMIS Neurosciences (PMN) focuses on developing antibodies to combat Alzheimer's disease, aiming for the targeted removal of pathogenic proteins in the brain. Future revenues are based on insurance reimbursements for innovative dementia therapy. Since the commercial launch of the drugs has not yet occurred, the company relies on equity capital, and the total assets amount to 33.10, which is reflected in this price chart illustrating value trends.

This metric is calculated inversely via return on assets (ROA), aggregating the total value of all corporate resources and liabilities to assess its fundamental scale. For ProMIS Neurosciences (PMN), which is currently in the clinical trial phase, the physical asset base is secondary to the potential of its Alzheimer's disease therapy, making the total asset dynamics on GURU.Markets an indicator of financial stability while awaiting research results.